Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-1.3
Enterprise Value $M6.3EPS (TTM) $-1.7Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.210-y EBITDA Growth Rate %--Quick Ratio6.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %120Current Ratio6.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-86.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-97.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M17.6ROIC % (ttm)-11,706.8Gross Margin Increase y-yN

Gurus Latest Trades with ONCS

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

ONCS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONCS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DHILLON AVTAR SDirector 2015-10-16Buy10,000$4.36-60.55view
Mohan-Peterson SheelaChief Legal Officer 2015-10-16Buy520$4.24-59.43view
DHILLON PUNITPresident and CEO 2015-10-16Buy10,000$4.25-59.53view
SLANSKY RICHARD BCFO 2015-07-06Buy150,000$6.12-71.9view
DHILLON PUNITPresident and CEO 2015-06-10Buy2,500$6.74-74.48view
MAIDA ANTHONY E IIIDirector 2014-03-20Buy22,800$0.81112.35view
DHILLON PUNITPresident and CEO 2014-03-19Buy50,000$0.8115view

Press Releases about ONCS :

Quarterly/Annual Reports about ONCS:

News about ONCS:

Articles On GuruFocus.com

More From Other Websites
ONCOSEC MEDICAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial... Jul 01 2016
OncoSec Presents Significant Advancements in Electroporation Technology for Immunotherapy Jun 28 2016
OncoSec Presents Significant Advancements in Electroporation Technology for Immunotherapy Jun 28 2016
OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016... Jun 16 2016
OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016... Jun 16 2016
ONCOSEC MEDICAL INC Financials Jun 15 2016
ONCOSEC MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jun 10 2016
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 Jun 09 2016
ONCOSEC MEDICAL INC Files SEC form 10-Q, Quarterly Report Jun 09 2016
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 Jun 09 2016
OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to... Jun 06 2016
OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to... Jun 06 2016
OncoSec Medical Incorporated's CEO Punit Dhillon Interviewed by The Life Sciences Report Jun 02 2016
OncoSec to Present at Scientific and Investment Conferences in June Jun 01 2016
OncoSec to Present at Scientific and Investment Conferences in June Jun 01 2016
OncoSec Closes $10 Million At-The-Market Registered Direct Offering May 26 2016
OncoSec Closes $10 Million At-The-Market Registered Direct Offering May 26 2016
ONCOSEC MEDICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... May 24 2016
OncoSec Announces $10 Million At-The-Market Registered Direct Offering May 23 2016
OncoSec Announces $10 Million At-The-Market Registered Direct Offering May 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)